Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 7/20 | 0.59 |
| ▸ | SENP1 | Q9P0U3 | 3/20 | 0.57 |
| ▸ | SENP5 | Q96HI0 | 2/20 | 0.57 |
| ▸ | SENP2 | Q9HC62 | 2/20 | 0.57 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.53 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.53 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.53 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.45 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.44 |
| ▸ | MEF2D | Q14814 | 1/20 | 0.44 |
| ▸ | DHPS | P49366 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7934108 | 0.86 | HDAC2 (0.46) | BACE1SENP1SENP5SENP2SIRT2 | |
| SCHEMBL7941948 | 0.86 | BACE1 (0.58) | BACE1SENP1SENP5SENP2SIRT2 | |
| SCHEMBL7940454 | 0.84 | HDAC2 (0.46) | BACE1SENP1SENP5SENP2SIRT2 | |
| SCHEMBL7942164 | 0.83 | BACE1 (0.59) | BACE1HDAC2HDAC1HDAC4HDAC6 | |
| SCHEMBL7942148 | 0.82 | BACE1 (0.61) | BACE1SENP1SENP5SENP2HDAC2 | |
| SCHEMBL7941663 | 0.80 | BACE1 (0.58) | BACE1SIRT2SIRT1SIRT3 | |
| SCHEMBL7942432 | 0.80 | BACE1 (0.69) | BACE1SIRT2SIRT1SIRT3HDAC2 | |
| SCHEMBL7942027 | 0.80 | BACE1 (0.58) | BACE1SENP1SENP5SENP2HDAC2 | |
| SCHEMBL7942157 | 0.80 | BACE1 (0.60) | BACE1HDAC4MEF2DHDAC6 | |
| SCHEMBL7939649 | 0.80 | BACE1 (0.68) | BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110237576-A1 | 2-AMINOPYRIMIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVES BOTH HAVING BACE1-INHIBITING ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2011-09-29 | — | — | US | disclosed |
| WO-2010047372-A1 | 2-AMINOPYRIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVE BOTH HAVING BACE1-INHIBITING ACTIVITY | 塩野義製薬株式会社 (JP) | 2010-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237576-A1 | 2-AMINOPYRIMIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVES BOTH HAVING BACE1-INHIBITING ACTIVITY | BACE1, APP, BACE2 | BACE1 1/4885SENP1 73/4885SENP5 300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.